Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gerresheimer AGGRRMF 56 EV-to-OCF is 14.16 as of Aug. 23, 2026, which is 11% below its 10-year median of 15.97. GuruFocus rates GRRMF with a GF Score™ of 56/100 and a GF Value™ of $192.51 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Gerresheimer AG ranks worse than 64.35% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Gerresheimer AG's Enterprise Value is $3,461 Mil.
Gerresheimer AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2025 was $244 Mil. Therefore, Gerresheimer AG's EV-to-OCF for today is 14.16.
The historical rank and industry rank for Gerresheimer AG's EV-to-OCF or its related term are showing as below:
GRRMF'
s EV-to-OCF Range Over the Past 10 Years
Min: 11.21 Med: 15.97 Max: 26.07
Current: 14.13
During the past 13 years, the highest EV-to-OCF of Gerresheimer AG was 26.07. The lowest was 11.21. And the median was 15.97.
GRRMF's EV-to-OCF is ranked worse than 64.35% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.73
vs GRRMF: 14.13
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gerresheimer AG (OTCPK:GRRMF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gerresheimer AG's PE Ratio (TTM) for today is calculated as:
Gerresheimer AG's share price for today is $31.14.
Gerresheimer AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.675.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gerresheimer AG EV-to-OCF Related Terms
Gerresheimer AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Gerresheimer AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's EV-to-OCF falls into.
Gerresheimer AG's current Enterprise Value is $3,461 Mil.
Gerresheimer AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gerresheimer AG (GRRMF) has a EV-to-OCF of 14.16 as of Aug. 23, 2026. This is 11% below median its historical median of 15.97. Over the past decade, Gerresheimer AG's EV-to-OCF has ranged from 11.21 to 26.07. According to the industry distribution chart, Gerresheimer AG ranks #547 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 64.4%.
Is Gerresheimer AG's EV-to-OCF too high?
Gerresheimer AG's current EV-to-OCF of 14.16 is 11% below median its 10-year median of 15.97. Over the past 10 years, this metric has ranged from a low of 11.21 to a high of 26.07. The Medical Devices & Instruments industry median EV-to-OCF is 7.73. Gerresheimer AG's value of 14.16 is 83.2% above this industry median. Based on the distribution chart, Gerresheimer AG ranks #547 out of 850 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gerresheimer AG has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #547 out of 850 companies for EV-to-OCF. This places Gerresheimer AG in the lower half of its industry. The industry median EV-to-OCF is 7.73. Gerresheimer AG's value of 14.16 is 83.2% above this benchmark. Historically, Gerresheimer AG's own EV-to-OCF has ranged from 11.21 to 26.07 over the past decade. While the company's 10-year median is 15.97 vs. the industry median of 7.73, Gerresheimer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.73, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gerresheimer AG's current EV-to-OCF of 14.16 is 83.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current EV-to-OCF is 14.16, which is 11% below median its own 10-year median of 15.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (GRRMF) is currently considered Possible Value Trap. The stock's GF Value™ is $192.51, compared to a current price of $31.14 — trading 83.8% below its estimated fair value. The current EV-to-OCF is 14.16, which is 11% below median its 10-year median of 15.97 and 83.2% above the Medical Devices & Instruments industry median of 7.73. Gerresheimer AG's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Gerresheimer AG (GRRMF), the current EV-to-OCF is 14.16 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (GRRMF) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of $31.14 is trading 83.8% below its estimated GF Value™ of $192.51.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for GRRMF:
EV-to-OCF: 14.16 (11% below median its 10-year median of 15.97)
GF Value™: $192.51 vs. price of $31.14 (83.8% below fair value)
Industry Position: 83.2% above the Medical Devices & Instruments median (#547 of 850)
No single metric tells the full story. See the GRRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
56GF Score
Get the complete analysis for GRRMF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRRMF has been successfully added to your 
